Progress toward newer guidelines of lipid management
The year 2016 in lipidology was relatively uneventful. There were no major randomized clinical trials published or presented addressing lipid management and no major lipid discovery made that could be immediately applicable in clinical practice. If I could summarize the current thinking of the clinical experts in the field of lipidology at this year's end, I would say that there were two major thoughts: that we as prescribing physicians need to prepare ourselves and the public for a probable further increase in the aggressiveness of treating atherogenic particles; and that we have accepted the futility of targeting HDL particles and the limitations in the utility of HDL cholesterol determination alone. New research has focused on the use of HDL as a predictor of risk, other than by the measurement of HDL cholesterol alone. In the current issue, we have included reviews addressing these considerations.